Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease.


Journal

Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633

Informations de publication

Date de publication:
08 Jul 2021
Historique:
received: 13 05 2021
accepted: 29 06 2021
entrez: 9 7 2021
pubmed: 10 7 2021
medline: 4 1 2022
Statut: epublish

Résumé

The University of California, San Diego Shortness of Breath Questionnaire (UCSDSOBQ) is a frequently used domain-specific dyspnea questionnaire; however, there is little information available regarding its use and minimum important difference (MID) in fibrotic interstitial lung disease (ILD). We aimed to describe the key performance characteristics of the UCSDSOBQ in this population. UCSDSOBQ scores and selected anchors were measured in 1933 patients from the prospective multi-center Canadian Registry for Pulmonary Fibrosis. Anchors included the St. George's Respiratory Questionnaire (SGRQ), European Quality of Life 5 Dimensions 5 Levels questionnaire (EQ-5D-5L) and EQ visual analogue scale (EQ-VAS), percent-predicted forced vital capacity (FVC%), diffusing capacity of the lung for carbon monoxide (DLCO%), and 6-min walk distance (6MWD). Concurrent validity, internal consistency, ceiling and floor effects, and responsiveness were assessed, followed by estimation of the MID by anchor-based (linear regression) and distribution-based methods (standard error of measurement). The UCSDSOBQ had a high level of internal consistency (Cronbach's alpha = 0.97), no obvious floor or ceiling effect, strong correlations with SGRQ, EQ-5D-5L, and EQ-VAS (|r| > 0.5), and moderate correlations with FVC%, DLCO%, and 6MWD (0.3 < |r| < 0.5). The MID estimate for UCSDSOBQ was 5 points (1-8) for the anchor-based method, and 4.5 points for the distribution-based method. This study demonstrates the validity of UCSDSOBQ in a large and heterogeneous population of patients with fibrotic ILD, and provides a robust MID estimate of 5-8 points.

Identifiants

pubmed: 34238283
doi: 10.1186/s12931-021-01790-0
pii: 10.1186/s12931-021-01790-0
pmc: PMC8265065
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

202

Subventions

Organisme : Boehringer Ingelheim
ID : 20R23666
Organisme : China Scholarship Council
ID : 201906260235

Références

COPD. 2015 Feb;12(1):31-7
pubmed: 24915470
Turk J Emerg Med. 2018 Aug 07;18(3):91-93
pubmed: 30191186
Respir Med. 2010 Sep;104(9):1350-5
pubmed: 20471238
Am J Respir Crit Care Med. 2017 Nov 15;196(10):1249-1254
pubmed: 28414524
Chest. 2018 Nov;154(5):1061-1069
pubmed: 30201408
Respir Med. 2012 Oct;106(10):1447-55
pubmed: 22801586
Respir Res. 2020 Mar 12;21(1):68
pubmed: 32164673
Lancet Respir Med. 2020 Feb;8(2):147-157
pubmed: 31578169
COPD. 2005 Mar;2(1):105-10
pubmed: 17136970
BMC Pulm Med. 2019 Nov 27;19(1):223
pubmed: 31771541
Chest. 2020 Jul;158(1S):S49-S56
pubmed: 32658652
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
J Cardiopulm Rehabil. 2005 Nov-Dec;25(6):370-7
pubmed: 16327533
N Engl J Med. 2019 Oct 31;381(18):1718-1727
pubmed: 31566307
Int J Behav Med. 1995;2(2):118-34
pubmed: 16250781
Chest. 1998 Mar;113(3):619-24
pubmed: 9515834
J Clin Epidemiol. 1999 Sep;52(9):861-73
pubmed: 10529027
Can Respir J. 2016;2016:3562923
pubmed: 27445528
Int J Med Educ. 2011 Jun 27;2:53-55
pubmed: 28029643
N Engl J Med. 2014 May 29;370(22):2083-92
pubmed: 24836312
Thorax. 2021 Jan;76(1):37-43
pubmed: 33023996
Rheumatology (Oxford). 2015 Aug;54(8):1369-79
pubmed: 25667436
Lancet Respir Med. 2020 Jan;8(1):25-33
pubmed: 31575509
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Respir Med. 2010 Feb;104(2):296-304
pubmed: 19815403
Eur Respir J. 2019 Sep 5;54(3):
pubmed: 31221807
Med Care. 2016 Jan;54(1):98-105
pubmed: 26492214
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1382-9
pubmed: 21940789
N Engl J Med. 2020 Sep 3;383(10):958-968
pubmed: 32877584
Am J Respir Crit Care Med. 2011 May 1;183(9):1231-7
pubmed: 21131468
COPD. 2014 Feb;11(1):26-32
pubmed: 23886071

Auteurs

Tao Chen (T)

Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada.
Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai, China.

Amy Po Yu Tsai (APY)

Department of Medicine, University of British Columbia, Vancouver, BC, Canada.

Seo Am Hur (SA)

Department of Medicine, University of British Columbia, Vancouver, BC, Canada.

Alyson W Wong (AW)

Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada.

Mohsen Sadatsafavi (M)

Respiratory Evaluation Sciences Program, Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada.

Jolene H Fisher (JH)

Department of Medicine, University of Toronto, Toronto, ON, Canada.

Kerri A Johannson (KA)

Department of Medicine, University of Calgary, Calgary, AB, Canada.

Deborah Assayag (D)

Department of Medicine, McGill University, Montreal, QC, Canada.

Julie Morisset (J)

Department of Medicine, University of Calgary, Calgary, AB, Canada.

Shane Shapera (S)

Department of Medicine, University of Toronto, Toronto, ON, Canada.

Nasreen Khalil (N)

Department of Medicine, University of British Columbia, Vancouver, BC, Canada.

Charlene D Fell (CD)

Department of Medicine, University of Calgary, Calgary, AB, Canada.

Helene Manganas (H)

Département de Médecine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.

Gerard Cox (G)

Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.

Teresa To (T)

Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.

Andrea S Gershon (AS)

Department of Medicine, University of Toronto, Toronto, ON, Canada.
Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada.
Sunnybrook Health Sciences Centre, Department of Medicine, University of Toronto, Toronto, ON, Canada.

Nathan Hambly (N)

Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.

Andrew J Halayko (AJ)

Departments of Internal Medicine and Physiology and Pathophysiology, University of Manitoba, Winnipeg, MB, Canada.

Pearce G Wilcox (PG)

Department of Medicine, University of British Columbia, Vancouver, BC, Canada.

Martin Kolb (M)

Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.

Christopher J Ryerson (CJ)

Department of Medicine, University of British Columbia, Vancouver, BC, Canada. chris.ryerson@hli.ubc.ca.
Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada. chris.ryerson@hli.ubc.ca.
Department of Medicine and Centre for Heart Lung Innovation, University of British Columbia, 8B Providence Wing, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada. chris.ryerson@hli.ubc.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH